Agnes Jager

16.3k total citations · 1 hit paper
227 papers, 7.0k citations indexed

About

Agnes Jager is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Agnes Jager has authored 227 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Oncology, 85 papers in Cancer Research and 67 papers in Genetics. Recurrent topics in Agnes Jager's work include Breast Cancer Treatment Studies (52 papers), BRCA gene mutations in cancer (39 papers) and Cancer Genomics and Diagnostics (37 papers). Agnes Jager is often cited by papers focused on Breast Cancer Treatment Studies (52 papers), BRCA gene mutations in cancer (39 papers) and Cancer Genomics and Diagnostics (37 papers). Agnes Jager collaborates with scholars based in Netherlands, Belgium and United States. Agnes Jager's co-authors include Coen D.A. Stehouwer, L.M. Bouter, Robert J. Heine, Giel Nijpels, Stefan Sleijfer, Joost Dekker, Piet J. Kostense, Ron H.J. Mathijssen, John W.M. Martens and Pieter J. Kostense and has published in prestigious journals such as JAMA, Nature Medicine and Nature Genetics.

In The Last Decade

Agnes Jager

212 papers receiving 6.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences

2020 262 citations C. Louwrens Braal, Elisabeth M. Jongbloed et al. profile →

Peers

Countries citing papers authored by Agnes Jager

Since Specialization

Citations

This map shows the geographic impact of Agnes Jager's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Agnes Jager with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Agnes Jager more than expected).

Fields of papers citing papers by Agnes Jager

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Agnes Jager. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Agnes Jager. The network helps show where Agnes Jager may publish in the future.

Co-authorship network of co-authors of Agnes Jager

This figure shows the co-authorship network connecting the top 25 collaborators of Agnes Jager. A scholar is included among the top collaborators of Agnes Jager based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Agnes Jager. Agnes Jager is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adverse health effects after breast cancer up to 14 years after diagnosis 2025 ·The Breast ·M. Heins, Kelly M. de Ligt, Janneke Verloop, Sabine Siesling, Joke C. Korevaar, Annette J. Berendsen, Daan Brandenbarg, Anneriet E. Dassen, Agnes Jager, Jacqueline G. Hugtenburg, (unknown)	0
2	Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial 2025 ·Nature Medicine ·Elisabeth M. Jongbloed, (unknown), Vanja de Weerd, Corine M. Beaufort, Kirsten Ruigrok-Ritstier, Mai N. Van, Jaco Kraan, Annette A. van Zweeden, (unknown), (unknown), Inge R. Konings, Gabe S. Sonke, Esther Oomen‐de Hoop, John W.M. Martens, Agnes Jager, Saskia M. Wilting	2
3	Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial 2025 ·European Journal of Cancer ·(unknown), (unknown), Inge R. Konings, (unknown), Vincent van der Noort, E. van den Pol, (unknown), (unknown), F. Van den Berkmortel, Helga Droogendijk, Danny Houtsma, Hendrika M. Oosterkamp, (unknown), Ester Siemerink, Jolien Tol, Annette A. van Zweeden, A. Elise van Leeuwen‐Stok, Gabe S. Sonke, Agnes Jager, Hedwig M. Blommestein	1
4	Barriers and facilitators for medical oncologists in the further implementation of mainstream genetic testing in breast cancer care in the Netherlands 2025 ·Familial Cancer ·C.L.D. de Jong, (unknown), Ellen G. Engelhardt, Agnes Jager, Margreet G.E.M. Ausems	0
5	352P Cost-effectiveness of CDK4/6 inhibitors in first- vs second-line for advanced breast cancer (ABC) in the phase III SONIA trial (BOOG 2017-03) 2024 ·Annals of Oncology ·(unknown), Stephen B. H. Kent, Inge R. Konings, (unknown), Vincent van der Noort, E. van den Pol, (unknown), (unknown), (unknown), Frans Erdkamp, Danny Houtsma, Hendrika M. Oosterkamp, (unknown), (unknown), J. Tol, Annette A. van Zweeden, A. Elise van Leeuwen‐Stok, Gabe S. Sonke, Agnes Jager, Hedwig M. Blommestein	1
6	Clinical decision support systems for multidisciplinary team decision-making in patients with solid cancer: Composition of an implementation model based on a scoping review 2024 ·Critical Reviews in Oncology/Hematology ·Mathijs P. Hendriks, Agnes Jager, (unknown), Janine A. van Til, Sabine Siesling	3
7	Cognitive function in patients with HR+ advanced breast cancer treated with endocrine therapy with or without CDK4/6 inhibitors in the SONIA trial. 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), (unknown), Joost A. Agelink van Rentergem, Ivar Vermeulen, Inge R. Konings, Agnes Jager, Gabe S. Sonke, Elsken van der Wall, Sanne B. Schagen	1
8	Machine learning-based somatic variant calling in cell-free DNA of metastatic breast cancer patients using large NGS panels 2023 ·Scientific Reports ·Elisabeth M. Jongbloed, Maurice P.H.M. Jansen, Vanja de Weerd, (unknown), Corine M. Beaufort, Marcel Reinders, Ronald van Marion, Wilfred F. J. van IJcken, Gabe S. Sonke, Inge R. Konings, Agnes Jager, John W.M. Martens, Saskia M. Wilting, (unknown)	2
9	The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer 2023 ·ESMO Open ·(unknown), Esther Oomen‐de Hoop, C. Louwrens Braal, (unknown), Jan C. Drooger, (unknown), (unknown), Stijn L.W. Koolen, Agnes Jager, Ron H.J. Mathijssen	10
10	Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer Have a Differential Impact on Downstream ER Signaling 2023 ·Cancers ·Lindsay Angus, Marcel Smid, Saskia M. Wilting, (unknown), Neeltje Steeghs, Inge R. Konings, Vivianne C. G. Tjan‐Heijnen, J.M.G.H. van Riel, Agnès J. van de Wouw, Edwin Cuppen, Martijn P. Lolkema, Agnes Jager, Stefan Sleijfer, John W.M. Martens	3
11	Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival 2023 ·npj Breast Cancer ·(unknown), Vanja de Weerd, Mai N. Van, Jaco Kraan, Marcel Smid, Joan B. Heijns, Jan C. Drooger, Johanna M. Zuetenhorst, (unknown), Agnes Jager, Stefan Sleijfer, John W.M. Martens, Saskia M. Wilting	6
12	Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor–Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial 2022 ·Journal of Clinical Oncology ·S.B. Vliek, Iris Noordhoek, Elma Meershoek‐Klein Kranenbarg, (unknown), Vincent O. Dezentjé, Agnes Jager, (unknown), Hein Putter, Annette W.G. van der Velden, Mathijs P. Hendriks, Sandra D. Bakker, Yvonne E A van Riet, Vivianne C. G. Tjan‐Heijnen, Johanneke E.A. Portielje, Judith R. Kroep, J.W.R. Nortier, Cornelis J.�H. van de Velde, Sabine C. Linn	8
13	Clinical Validity of 16α-[¹⁸F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer 2022 ·Journal of Clinical Oncology ·(unknown), Jorianne Boers, Sjoerd G. Elias, Andor W.J.M. Glaudemans, Erik F. J. de Vries, Geke A.P. Hospers, Michel van Kruchten, Evelien Kuip, Agnes Jager, C. Willemien Menke‐van der Houven van Oordt, Bert van der Vegt, Elisabeth G.E. de Vries, Carolina P. Schröder	38
14	Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study 2021 ·The Breast ·(unknown), (unknown), B.A.M. Heemskerk-Gerritsen, Ewout W. Steyerberg, Michael Hauptmann, Irma van de Beek, Klaartje van Engelen, Marijke R. Wevers, E. Gómez, Margreet G.E.M. Ausems, (unknown), Christi J. van Asperen, Muriel A. Adank, (unknown), (unknown), Agnes Jager, Marjanka K. Schmidt, Maartje J. Hooning	5
15	A Systematic Review of the Use of Circulating Cell-Free DNA Dynamics to Monitor Response to Treatment in Metastatic Breast Cancer Patients 2021 ·Cancers ·Elisabeth M. Jongbloed, (unknown), Stefan Sleijfer, John W.M. Martens, Agnes Jager, Saskia M. Wilting	6
16	Measuring Quality of Life Using Patient-Reported Outcomes in Real-World Metastatic Breast Cancer Patients: The Need for a Standardized Approach 2021 ·Cancers ·(unknown), (unknown), (unknown), Carin A. Uyl‐de Groot, Elham Hedayati, Maria Margarete Karsten, Agnes Jager, Linetta B. Koppert	20
17	Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects 2018 ·Clinical Cancer Research ·Titia G. Meijer, Nicole S. Verkaik, Anieta M. Sieuwerts, Job van Riet, Kishan A.T. Naipal, Carolien H. M. van Deurzen, Michael A. den Bakker, Hein F.B.M. Sleddens, (unknown), (unknown), Winand N.M. Dinjens, Esther H. Lips, Petra M. Nederlof, Marcel Smid, Harmen J.G. van de Werken, Roland Kanaar, John W.M. Martens, Agnes Jager, Dik C. van Gent	47
18	Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers 2016 ·Cancer Epidemiology Biomarkers & Prevention ·Janet R. Vos, Jan C. Oosterwijk, Cora M. Aalfs, Matti A. Rookus, Muriel A. Adank, Annemarie H. van der Hout, Christi J. van Asperen, E. Gómez, Arjen R. Mensenkamp, Agnes Jager, Margreet G.E.M. Ausems, Marian J.E. Mourits, Geertruida H. de Bock	5
19	Angiogenesis- and Hypoxia-Associated Proteins as Early Indicators of the Outcome in Patients with Metastatic Breast Cancer Given First-Line Bevacizumab-Based Therapy 2016 ·Clinical Cancer Research ·Siu W. Lam, Nienke M. Nota, Agnes Jager, Monique M.E.M. Bos, (unknown), Ankie M.T. van der Velden, Johanneke E.A. Portielje, Aafke H. Honkoop, Harm van Tinteren, Epie Boven	17
20	Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment 2014 ·Clinical Cancer Research ·Kishan A.T. Naipal, Nicole S. Verkaik, Najim Ameziane, Carolien H. M. van Deurzen, Petra ter Brugge, Matty Meijers, Anieta M. Sieuwerts, John W.M. Martens, Mark J. O’Connor, Harry Vrieling, Jan H.J. Hoeijmakers, Jos Jonkers, Roland Kanaar, Johan P. de Winter, Maaike P.G. Vreeswijk, Agnes Jager, Dik C. van Gent	124

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact